These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35565407)
1. Clinical Considerations for Immunoparesis in Multiple Myeloma. Chahin M; Branham Z; Fox A; Leurinda C; Keruakous AR Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565407 [TBL] [Abstract][Full Text] [Related]
2. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH; Duggan P; Neri P; Chaudhry A; Tay J; Bahlis N Leuk Lymphoma; 2018 Aug; 59(8):1920-1926. PubMed ID: 29160734 [TBL] [Abstract][Full Text] [Related]
3. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. Isola I; Moreno DF; Moga E; Mena MP; Tovar N; Rodríguez-Lobato LG; Oliver-Caldés A; Salgado MC; Brasó-Maristany F; Yagüe J; Cibeira MT; Prat A; Rosiñol L; Bladé J; Fernández de Larrea C Ann Hematol; 2021 Dec; 100(12):2997-3005. PubMed ID: 34463804 [TBL] [Abstract][Full Text] [Related]
4. Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis. Chen Y; Chen Z; Cao J; Lin L; Li J Hematology; 2024 Dec; 29(1):2329378. PubMed ID: 38470208 [TBL] [Abstract][Full Text] [Related]
5. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. Chakraborty R; Rybicki L; Nakashima MO; Dean RM; Faiman BM; Samaras CJ; Rosko N; Dysert H; Valent J; Anwer F Br J Haematol; 2020 Jun; 189(6):1074-1082. PubMed ID: 32108328 [TBL] [Abstract][Full Text] [Related]
6. Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation. Gao W; Li J; Jian Y; Yang G; Wu Y; Li Y; Len Y; Liu A; Tian Y; Wang H; Zhou H; Zhang Z; Chen W Int J Hematol; 2019 Feb; 109(2):169-174. PubMed ID: 30311142 [TBL] [Abstract][Full Text] [Related]
7. Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation. Gao W; Li J; Wu Y; Li Y; Leng Y; Liu A; Yang G; Tian Y; Wang H; Wang G; Wu Z; Ren Z; Chen W Ann Hematol; 2019 May; 98(5):1177-1184. PubMed ID: 30610278 [TBL] [Abstract][Full Text] [Related]
8. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Caro J; Cairns D; Menzies T; Boyle E; Pawlyn C; Cook G; Kaiser M; Walker BA; Owen R; Jackson GH; Morgan GJ; Heaney J; Drayson MT; Davies FE Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e279-e284. PubMed ID: 34876373 [TBL] [Abstract][Full Text] [Related]
9. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Heaney JLJ; Campbell JP; Iqbal G; Cairns D; Richter A; Child JA; Gregory W; Jackson G; Kaiser M; Owen R; Davies F; Morgan G; Dunn J; Drayson MT Leukemia; 2018 Aug; 32(8):1727-1738. PubMed ID: 29925902 [TBL] [Abstract][Full Text] [Related]